Effect of angiotensin receptor blockers on blood pressure control among euvolemic hypertensive hemodialysis patients: a randomized controlled trial

Phase 3

Active, not recruiting

• Conditions: hypertension in End stage renal disease; Renal and Urogenital - Kidney disease; Cardiovascular - Hypertension

• Registration Number: ACTRN12615001322527
• Lead Sponsor: niversiti Sains Malaysia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-12-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Euvolumic patients with blood pressure more than 140/90 mmHg post dialysis will be included for the study.
On basis of expert opinion from nephrologists, patient 30-80 years were included for current study.
Finally, patients undergoing dialysis duration of at least 12 months, 2 to 3 HD sessions weekly and Patients willing to participate were included for current study.

Exclusion Criteria

Patients with amputations, neoplasm and cystic kidneys, unwilling to participated in the study.

Patients already on ARBs and Patients with symptomatic hypotension or SBP less than 110 mm Hg were excluded from the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the primary end point includes attaining post dialysis systolic blood pressure of <140mmHg and maintaining it for three weeks. Outcome will be assessed on proportion of patients achieving systolic blood pressure of <140mmHg for three weeks within 8 months of study duration<br>outcomes will be monitored by blood pressure monitoring device (automatic sphygmomanometer). Blood pressure will be monitored 30 minutes post dialysis till study end point is achieved or maximum duration of 8 months[All End stage renal failure patients undergoing dialysis thrice a week will be recruited for current study.. Blood pressure reading will be taken 30 mins post dialysis after every session ( thrice/week) till study end point or maximum period of 8 months]

Secondary Outcome Measures

Name	Time	Method
The secondary point will be all cause of mortality.<br>A validated data collection tool will be formed to record all patient finding related to study. in case of mortality, all patient records and consultation with the doctor will be assured to confirm the cause of mortality<br>[8 months]